Laurus Labs Limited
Corporate Office
2nd Floor, Serene Chambers, Road No. 7
Banjara Hills, Hyderabad - 500034, Telangana, India
T +91 40 39804333 / 2342 0500 / 501
F +91 40 3980 4320

LAURUS Labs
Knowledge . Innovation . Excellence

November 01, 2018

To	To
The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25th Floor, Dalal Street Mumbai – 400001 **Code: 540222**	The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 **Code: LAURUSLABS**

Dear Sirs,

Sub: **Investors/Analysts Presentation**

Please refer to our letter dated October 29, 2018, wherein we have intimated the schedule of Investors/Analysts call to be held on November 2, 2018. In this connection, we enclose herewith the presentation to the Investors/Analysts on the Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30, 2018.

The presentation is also being uploaded on the website of the Company – www.lauruslabs.com.

Please take the information on record.

Thanking you,

Yours sincerely,
For Laurus Labs Limited

LAURUS LABS LIMITED Hyderabad

G. Venkateswar Reddy
Company Secretary

LAURUS LABS LIMITED

Q2 & H1 FY19

RESULTS PRESENTATION

November 01, 2018

BSE: 540222
NSE : LAURUSLABS

Disclaimer

Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements.

Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

Business Snapshot

	LAURUS Generics Active Pharmaceutical Ingredients & Intermediates	LAURUS Generics Finished Dosage Forms	LAURUS Synthesis Contract Development & Manufacturing Services	LAURUS Ingredients Specialty Ingredients for Nutraceutical & Allied Industry
Overview	• Development, manufacture and sale of active pharmaceutical ingredients (APIs) and advanced intermediates	• Developing and manufacturing oral solid formulations	• Contract development and manufacturing services for global pharmaceutical companies	• Sale and manufacture of specialty ingredients for use in nutraceuticals, dietary supplements and cosmeceutical products
Product and Service Offerings	• Anti-retroviral (ARV) • Hepatitis C • Oncology • Large volume APIs for cardio-vascular, antidiabetic, anti-asthmatic, gastroenterology therapeutic areas • Small volume APIs for the ophthalmic therapeutic area	• ARVs • Anti-diabetic • Cardio Vascular • Proton Pump Inhibitors • CNS	• Commercial scale contract manufacturing • Clinical phase development and supplies • Analytical and research services • Integrated Drug Substance and Drug Product offerings	• Nutraceuticals, dietary supplements and cosmoceutical products • Set up a dedicated block in Unit 4 for global partner , C2 Pharma
Filings	• Commercialized 50+ products • 50 DMFs filed	• Filed 16 ANDAs with USFDA • 2 dossier in Canada, 5 dossiers in Europe, 5 dossier with WHO, 2 dossier in South Africa, 2 dossier in India & 59 in ROW. In addition, completed 3 products validations. • 2 ANDAs Approved	• Commenced commercial supplies from Unit 5	• NA
Infrastructure	• 4 Manufacturing facilities, (2,829 KL) (1) (2)	• 5 bn Units / year capacity.	• Dedicated manufacturing (Unit – 5) Capacity (125 KL) for Aspen. Dedicated facilities in other units	• Manufacturing facilities(2)

(1) Includes ingredients products excluding Unit 2 API & Kilo lab capacity

(2) APIs , Ingredients and Synthesis (other than Aspen supplies) are manufacturing at Unit 1,3 ,4 & 6

Strategy in Motion

ARV & HEP-C

- Significant increase in HIV patient population with revised WHO guidelines
- New opportunities in Second Line therapies
- ARV drugs patent expiry in US & European markets
- Strong opportunity in Hepatitis C in emerging markets

Capitalize on our Leadership Position in APIs in Select, High-Growth Therapeutic Areas . Foray into regulated markets

Oncology & Other APIs

- Leadership in select Oncology API. Launching few more products in FY19 & beyond in regulated markets
- Leverage process chemistry skills to expand API product portfolio in other growing therapeutic areas
- Contract manufacturing of generic APIs

Further expand our API Portfolio in key therapeutic areas such as Oncology, CVS, Anti-Diabetic & Ophthalmology

FDFs

- Leverage API capabilities; capture operating efficiencies through backward integration
- 2 Partnerships in place for commercialization of FDFs in US market.
- Generate revenue from the emerging markets by participating through tenders.
- Setting up our own front end in the US market
- Looking to capitalize in other EMs and developed markets
- Contract manufacturing for European Customers

Leverage API Cost Advantage for Forward Integration into Generic FDF
Therapeutic Focus Areas – ARV, CVS, CNS, PPI & Anti Diabetic

Synthesis

- Services offering development and manufacturing across all clinical stages
- Backward integration of key starting materials and intermediates for new chemical entities
- Contract with Aspen for supply of hormonal intermediates
- Strong pipeline backed by successful execution of various projects from pre clinical to commercial in both Development & Manufacturing.

Develop our Synthesis Business through various global Innovators and Biotechs' by leveraging our R&D and manufacturing strengths

Ingredients

- Leverage process chemistry skills to strengthen presence in nutraceutical and cosmeceutical sectors as they adopt quality standards at par with pharma industry

Expanding from Synthetic process to Natural Extraction

Transformation of Business Model



2006
- Set up the R&D Centre at IKP, Knowledge Park, Hyderabad

2007
- Commenced commercial operations at Unit 1

2012
- Investment of INR 600 Mn by FIL Capital Management and Promoters.

2013
- Crossed INR 10 billion of revenues

2014
- Incorporated First Subsidiary in USA, Laurus Inc.
- Investment of INR 3000 Mn by Warburg Pincus

2015
- Successfully listed on BSE & NSE
- Filed first ANDA for US market
- Acquired 100% stake in Sriam Labs Pvt Ltd.
- Commenced commercial operations at Unit 3,
- Forged partnership with NATCO

2016
- Crossed INR 20 billion of revenue
- Commenced commercial operations from Unit 4
- Incorporated a subsidiary in Germany
- Unit 2-Formulations, inspected by USFDA with Zero 483 observations
- Launched maiden FDF product Tenofovir in USA, Canada and emerging markets.
- Certified as Great Place to Work for the year 2018

2017
- Commenced commercial operations at Unit 2
- Commenced commercial supplies from Unit 5 for Aspen
- Launched Velpatasvir in the HEP - C segment
- Received EIR from USFDA for Units 1,2 & 3
- Incorporated subsidiaries in UK & USA

Formulations Business – Global Approach

- Extensive Manufacturing capabilities across markets with commitment to maintain highest quality standards – "**One Quality Standard for All Markets**"
- Current FDF Manufacturing Capacity - **5 bn tab/caps with total Capex investment of ~INR 4,250 mn**
- **Tenofovir (TDF) ANDA rights transferred to CASI Pharma for a consideration of ~$3 Mn of which ~$2 Mn will be received by March 2019 based on Milestone Payments. Laurus continues to sell TDF in other countries.**
- **Dossier Filings**

Therapy	US ANDA	Europe	Canada	Africa	Asia
ARV	8	3	2	50	6
Anti- Diabetic	3	1	-	3	2
CVS	1	-	-	-	-
CNS	1	1	-	-	-
Autoimmune	1	-	-	-	-
Pulmonary (IPF)	2	-	-	-	-
Total	**16 ***	**5**	**2**	**53**	**8**

*** Have 2 Para IV opportunities and ~7 FTF opportunities in US market with addressable current market size of $10 bn**

- **Inspection status for Formulations manufacturing Unit (Unit 2)**

Region	Agency	Audit Status
USA	USFDA	EIR Received
Europe	JAZMP – Slovenia, and BGV Hamburg	Certificate Received
ROW	WHO – Geneva	Certificate Received
Europe	JAZMP – Slovenia, and BGV Hamburg	Certificate Received
Africa	Tanzania FDA, National Drug Authority – Uganda, PMPB – Malawi, and Pharmacy & Poisons Board – Kenya	Approvals Received

Formulations Strategy for Developed Markets

Overview	**US, EU, Canada remains our key focus markets by focusing on the combination of commercialised high volume products, first to file, Para IV opportunity based on IP to address short, medium and long term strategy.**
Target Markets	USA, Europe and Canada
Key Therapeutic Areas	ARV, Anti Diabetic, CVS, CNS and others
US Filings	• Cumulatively filed 16 ANDAs • Have filed 2 Para IV and 7 FTFs with opportunities worth over $ 10 Billion* annual sales in US • Targeting ~10 ANDA Filings per year
US Approvals	2 Approvals received
US Partnerships	• Re negotiated partnerships with DRL and Rising Pharma by reducing products under partnership from 18 to 7 products. 11 products will be developed by Laurus which was concluded in the second quarter by paying necessary development fees back to the partner • Exploring possibility of marketing licensed products by Laurus.
EU Overview	Followed with partnering model for supply of FDF products and also contract manufacturing. Incremental expenditure incurred for filings in 2nd quarter
EU Filings	Filed 5 Dossiers for ARV & Anti Diabetic products
Approach	• To participate in various country specific tenders and partnering for marketing • Commercial supplies under Contract Manufacturing for an European Customer will commence in Q3 2018

* Source: IMS Q3 CY 2017

Formulations Strategy for Emerging Markets

Overview	**Emerging Markets of Africa & ARV Tender business remains the forefront of our Formulations Strategy. Integrated approach is key to success and Laurus is well positioned to garner this opportunity**
Target Market	Emerging Markets – Global fund tenders, WHO Tender, PEPFAR Tender, Various African In-Country Tenders
Therapeutic Areas	ARV
Addressable Market Size	• ~$ 2 Billion in Generic Accessible markets • Commenced Tenofovir (TDF) Sales in Africa and awaiting participation in tenders for TLD (Tenofovir, Lamivudine, Dolutegravir) Combination
Filings	Over 50 product registrations filed in various African & Asian Countries
Approvals	• Have received approval for TLD under Global Fund-ERP which enables us to participate in various In-Country Tenders. • Tenofovir approved by WHO and USFDA
Future Filings	• TLE (Tenofovir, Lamivudine, Efavirenz) combination to be filed in Nov'2018 • Development of other combinations for first line and second line therapy is active and expected to be ready for filing by Dec 2019.
Growth Potential	Total patients growth is expected to be in high single digit and treatment to reach about 25 mn patients by 2022

Strong R&D Capabilities

- **"Research-first"** approach – Set up dedicated R&D center in Hyderabad in 2006 prior to commissioning API manufacturing facility in 2007 and further expansion completed in 2017.
- R&D team comprising 800 plus scientists (~24% of total employee strength) including over 55 PhDs
- Kilo Lab at R&D center accredited by international regulators
- Currently setting up new R&D center in Visakhapatnam

Key Accreditations

USFDA

FDA S Korea

PMDA Japan

WHO

Increasing R&D Spend (INR mn)



50+	50	230	69	16
Products commercialized since inception	Filed DMFs	Patents filed	Patents granted	ANDAs & NDA / Dossiers filed

- R & D spent includes OPEX, CAPEX and RMC of FDF validation batches
- FY 17 numbers are high due to additional CAPEX and initial FDF validation batches

Quality Focus & Regulatory Audits

We maintain consistent quality, efficiency and product safety.

We have adopted uniform manufacturing standards across all facilities to achieve standardized quality for all markets. Good manufacturing practices across all the manufacturing facilities, encompassing all areas of business processes right from supply chain to product delivery.

Laurus' Philosophy

"One Quality Standard for all markets"

Regular Inspection at different manufacturing units

2018	USFDA
2017	WHO, USFDA, EU (Germany)
2016	USFDA
2015	WHO, USFDA, EU (Germany)
2014	WHO, USFDA, CDSCO
2013	WHO
2012	USFDA
2011	KFDA, USFDA, WHO
2010	MHRA
2009	TGA, USFDA

Manufacturing Facilities at Parawada, Vizag

Unit-I

- Located at Jawaharlal Nehru Pharma City, Vishakhapatnam, India.
- API manufacturing facility and includes capacity for ingredients, synthesis and contract manufacturing.
- Commenced operations in 2007.
- 315 reactors with 1,141 Kilo Liters capacity.
- Received approvals from US FDA, WHO-Geneva, NIP Hungary, KFDA & PMDA.

Unit-III

- Located at Jawaharlal Nehru Pharma City, Vishakhapatnam, India.
- API manufacturing facility and includes capacity for ingredients, synthesis and contract manufacturing.
- Commenced operations in 2015.
- 194 reactors with 1,350 Kilo Litres capacity.
- Received approvals from USFDA, WHO – Geneva, & NIP – Hungary .

Unit-V

- Located at Jawaharlal Nehru Pharma City, Vishakhapatnam, India. (SEZ)
- A dedicated Hormone and Steroid facility for Aspen
- Commenced operations in 2017.
- 46 reactors with 125 Kilo Litres capacity .

Manufacturing Facilities at Achutapuram, Vizag

Unit-II

- Located at APIIC, Achutapuram, Visakhapatnam, India. (SEZ)
- FDF and API manufacturing facility
- Commenced operations in 2017.
- FDF - capacity of 5 bn tablets per year.
- API block with 12 reactors with 83 Kilo Liters capacity.
- Received approvals from BVG Hamburg Germany, USFDA, WHO – Geneva

Unit-IV

- Located at APIIC, Achutapuram, Visakhapatnam, India. (SEZ)
- API manufacturing facility and includes capacity for ingredients, synthesis and contract manufacturing.
- Commercial operations in 2018
- 32 reactors with 85 Kilo Liters capacity.

Unit-VI

- Located at APIIC, Achutapuram, Visakhapatnam, India.
- API manufacturing facility.
- Commercial operations in 2018
- 42 reactors with 253 Kilo Liters capacity.
- Unit acquired through slump sale from Sriam Labs (100% Subsidiary)

Business Highlights – Q2 & H1 FY 19

Overall

- Total Income at INR 11,273 Mn during the H1 FY19 (Y-o-Y) grown by 11 % and INR 5,883 Mn during quarter grown by 9% Y-o-Y.
- R & D spent of INR 794 Mn and 7 % as percentage of sales during H1 FY19.

Generic API

- Filed 230 patent applications and 69 patent granted as on Sept 30, 2018
- Capacity expansion completed for Lamivudine.
- USFDA inspection scheduled for Unit VI from 29th October 2018

Synthesis & Ingredients

- Strong pipeline of new business opportunities from Innovator/Pharma companies will fuel further growth.
- Initiation of commercial supplies to an innovator's NDA filing in Q2
- Initiation of Integrated service offering (Drug Substance and Drug Product)

Generic FDF

- Tenofovir (TDF) ANDA rights transferred to CASI Pharma for a consideration of ~$3 Mn of which ~$2 Mn will be received by March 2019 based on Milestone Payments. Laurus continues to sell TDF in other countries.
- 3 product validations completed for formulation apart from filling of 16 ANDAs
- FDF Opex of INR 814 Mn which includes INR 437 Mn related to the R&D during H1 FY19.
- Successfully completed JAZMP (Slovenia Regulatory Authority) audit for European Supplies and commercial production for contract manufacturing started in October 2018.

Performance Highlights - Abridged Profit & Loss statement

Particulars (Rs. mn)	Q2 FY19	Q2 FY18	Growth % (Q2 FY19 Vs. Q2 FY 18)	Q1 FY19	Growth % (Q2 FY19 Vs. Q1 FY 19)	H1 FY19	H1 FY18	Growth % (H1 FY19 Vs. H1 FY 18)
Total Revenues from Operations (Net)	**5,883**	**5,386**	**9.2%**	**5,390**	**9.1%**	**11,273**	**10,170**	**10.8%**
Total Expenditure*	5,770	4,756		5,190		10,960	9,064	
EBITDA	**862**	**1,192**	**-27.7%**	**825**	**4.5%**	**1,687**	**2,226**	**-24.2%**
Margins	14.7%	22.1%		15.3%		15.0%	21.9%	
PBT	**218**	**696**	**-68.7%**	**226**	**-3.5%**	**444**	**1,248**	**-64.4%**
Margins	3.7%	12.9%		4.2%		3.9%	12.3%	
PAT	**162**	**488**	**-66.8%**	**166**	**-2.4%**	**328**	**877**	**-62.6%**
Margins	2.8%	9.1%		3.1%		2.9%	8.6%	
EPS (Diluted)	**1.5** (Not annualised)	**4.6** (Not annualised)	**-67.4%**	**1.6** (Not annualised)	**-6.3%**	**3.1** (Not annualised)	**8.2** (Not annualised)	**-62.2%**

** Total expenditure excluding RMC*

- Exchange rate per US$ stood at INR 65.04 by 31st Mar 18, INR 68.58 by 30th Jun 18, INR 72.55 by 30th Sep 18 and depreciated by INR 3.54 (5.44%) and INR 3.97 (5.79%) respectively. Rupee depreciation resulted INR 168 mn loss in Q2 and most of it is unrealized loss (INR 154 mn). The unrealized loss on account of long term foreign currency loans payable over period of around 5 years.

- Additional cost of around INR 140 Mn incurred in Q 2 for FDF business on transfer of rights on profit sharing on 11 products from DRL and Rising pharma, regulatory filing costs in Europe (3 Dossiers), regulatory filing costs in USA (4 ANDAs).

- Major Raw material procurement prices increased significantly due to shortage of intermediates due to environmental issues and closure of manufacturing facilities in China resulted lower Gross margins. This will be mitigated from third quarter through alternative sourcing/in house manufacturing and working on sales price increases with customers.

Note: Consolidated financials as per Ind-AS

Drivers of Revenue – Division wise revenue breakup

- **Total Revenues** grew by 9% for the quarter (Y-o-Y) and 11% for H1 (Y-o-Y)
- **ARV** Segment registered a healthy growth of over 17% in H1 (Y-o-Y) on the back of improved volumes
- **HEP-C** business continues to remain muted. However, the segment showed a growth of 24% for the quarter (Y-o-Y) and registered 44% de-growth for H1 (Y-o-Y)
- **Oncology** business remained steady and grew by 22% for the quarter (Y-o-Y) & 10% for H1 (Y-o-Y)
- **Other API** sales grew over 28 % for the quarter (Y-o-Y). Sales were lower in H1 (Y-o-Y) because of lower sales in Q1 FY19.
- **Synthesis** Business continues to report robust revenue growth growing by 58% for the quarter (Y-o-Y), and 62% in H1 (Y-o-Y), with increase in revenue from Unit 5 and also with improved contribution from CMO business
- **Ingredients** revenue grew 8% for H1(Y-o-Y)
- **Generic FDF** business improved its contribution in H1 FY19 crossing first $1 Mln mark; through US & emerging markets sales



Segments (INR Mn)	Q1 FY19	Q2 FY19	H1 FY19	Q2 FY18	H1 FY 18	Growth Q2 (Y-o-Y)	Growth H1 (Y-o-Y)
ARV	3,710	3,882	7,592	3,811	6,501	2%	17%
HEP-C	241	344	585	277	1,044	24%	-44%
Oncology	440	465	905	380	821	22%	10%
Other API	217	533	750	415	844	28%	-11%
Synthesis	541	530	1,071	336	663	58%	62%
Ingredients	190	107	297	149	274	-28%	8%
Generics FDF	51	22	73	18	23	22%	217%
Total Revenue	**5,390**	**5,883**	**11,273**	**5,386**	**10,170**	**9%**	**11%**

Note: Consolidated financials as per Ind-AS

Abridged Balance Sheet

Particulars (Rs. mn)	As on 31.03.2018	As on 30.09.2018
EQUITY AND LIABILITIES		
Shareholders' funds		
Share capital	1,060	1,064
Reserves and surplus	13,766	13,862
Non-current liabilities	2,272	3,898
Current liabilities	13,069	13,911
Total	**30,167**	**32,735**
ASSETS		
Non-current assets	1,252	1,343
Fixed assets	16,440	17,052
Current assets	12,475	14,340
Total	**30,167**	**32,735**

Particulars (Rs. mn)	As on 31.03.2018	As on 30.09.2018
BORROWINGS		
Long term borrowings	1,417	2,912
Current maturities of LTB	797	755
Short term borrowings	7,585	7,733
TOTAL	**9,799**	**11,400**

Note: Consolidated financials as per Ind-AS

Established Track Record Of Delivering Growth
– Efficient Use of Capital and Prudent Leverage







Significant investments in FDF, Unit 4 and Unit 6.

FY 19 H1 ratios are calculated based on H1 annualized.

Note: Based on consolidated financials as per Ind AS

(1) Pre-tax RoCE is calculated as EBIT/Average Capital Employed. Capital employed is defined as Net Worth + Long Term and Short Term Borrowings + Current Portion of Long Term Borrowing - Cash

(2) RoE is calculated as PAT/Average Net Worth

Management Team

Chandrakanth Chereddi

ED & Head, Generics FDF & Strategy

Ravi kumar V V

ED &CFO

G Venkateshwar Reddy

CS and Sr. GM – Legal & Secretarial

Tom Versosky

President FDF North America

Dr. Prafulla Kumar Nandi

SVP, Global Regulatory Affairs (Formulations)

Dr. GSR Anjaneyulu

Exec. VP & Head, Sriam Labs

Dr. Satyanarayana Chava

Founder & CEO

M. Bhaskaraiah

SVP – SCM

C. Krishna Chaitanya

Head, Synthesis & Ingredients

Dr. V Uma Maheswer Rao

Exec. VP & Head, Chemical R&D

Srinivasa Rao S

Exec. VP – Operations

Martyn Peck

SVP – Business Development, Generics - API

Dr. Lakshmana Rao C V

ED & Head, Quality

Corporate Governance

Executive Directors	
Name	**Background**
Dr Satyanarayana Chava	▪ Whole-time Director, Founder and Chief Executive Officer
Ravi Kumar V V	▪ Whole-time Director and CFO
Chandrakanth Chereddi	▪ Whole-time Director and Head of Generic FDF and Strategy
Dr Lakshmana Rao C V	▪ Whole-time Director and Head, Quality

Non-Executive Directors	
Name	**Background**
Dr. M. Venu Gopala Rao	▪ Non Executive Chairman and Independent Director
Narendra Ostawal	▪ Managing Director of Warburg Pincus India Private Limited
Aruna Rajendra Bhinge	▪ Independent Director; Former Head of Food Security Agenda, APAC at Syngenta India Limited
Dr. Rajesh Koshy Chandy	▪ Independent Director; Professor of Marketing at the London Business School
Ramesh Subrahmanian	▪ Independent Director; Founder and Director of Alchemy Advisors
Dr. Ravindranath Kancherla	▪ Independent Director and Founder-Member and Treasurer of ELSA of Asia in Singapore and Chairman of Global Hospitals

Ownership Structure

Corporate Structure



All are 100% Subsidiaries

Shareholding pattern *



* As of 30th September 2018

Pharmaexcil Outstanding Exports Award 2017-2018

Laurus Labs bags the prestigious Pharmaexcil Outstanding Exports Award 2017-2018 in Pharmaceutical Sector.

Mr. V V Ravi Kumar, ED&CFO, Laurus Labs received the award on 14 of September 2018 in a grand ceremony held in Hyderabad.

Global Generics & Biosimilars API Supplier of the year award 2018

Laurus Labs is a Fortune 500 Company, Great Place To Work and one of the India's Best Workplace in 2018

Laurus Labs is listed in the Fortune 500 Companies List in India

Laurus Labs is certified as "Great Place to Work" for the year 2018.

GREAT PLACE TO WORK®
CERTIFIED
JAN 2018 - DEC 2018
INDIA

Laurus Labs is recognized as one of the Best Work Places in Biotechnology, Pharmaceuticals & Health Care sector for the year 2018

India's Best Companies To Work For 2018
A STUDY BY THE ECONOMIC TIMES | Great Place To Work.

Results Conference Call

Results conference call on Friday November 02, 2018 at 4:00 PM IST

Details of the conference call are as follows:

Timing	4:00 PM IST on Friday, November 02, 2018
Conference dial-in Primary number	+91 22 6280 1214
India Local access Number	+91 7045671221 Available all over India
Singapore	6531575746
Hong Kong	85230186877
USA	13233868721
UK	442034785524

Contact us

About Laurus Labs Ltd.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus also manufactures APIs in Oncology and other therapeutic areas. Its strategic and early investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area. Laurus Labs also forayed into Finished Dosages Forms capabilities on the back of existing strengths in APIs. The Company is also driving growth opportunities in the Synthesis and Ingredients businesses. **Corporate Identification No: L24239AP2005PLC047518.**

*For more information about us, please visit **www.lauruslabs.com** or contact:*

Monish Shah
Tel: +91 040 3980 4366
Email: investorrelations@lauruslabs.com

Pavan Kumar N
Tel: +91 040 3980 4380
Email: mediarelations@lauruslabs.com

Thank You